Teleflex (TFX) Stock Price & Analysis
TFX Stock Chart & Stats
- Day’s Range
- MXN 2,412.04 - MXN 2,412.04
- 52-Week Range
- MXN 1,825.00 - MXN 2,412.04
- Previous Close
- MXN 2,412.04
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 111.29B
- Enterprise Value
- MXN 8.09B
- Total Cash (Recent Filing)
- MXN 300.16M
- Total Debt (Recent Filing)
- MXN 2.87B
- Price to Earnings (P/E)
- ―
- Beta
- -0.06
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 35.57
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.97%
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-driven Demand
Teleflex benefits from recurring consumable demand embedded in routine and complex hospital procedures. Broad use across vascular access, anesthesia, surgery, urology and critical care can support repeat purchasing, helping make revenue less dependent on one-time capital sales.
Deleveraging And Capital Allocation
The OEM divestiture materially improves strategic focus while providing cash to reduce debt and repurchase shares. Lower pro forma net leverage and reduced interest expense can strengthen financial flexibility, support earnings, and provide greater capacity for future investment.
Innovation And Clinical Pipeline
FDA approval for EZPLAZ and continued Freesolve clinical progress expand Teleflex’s innovation pipeline in emergency medicine and interventional therapies. Combined with R&D at 7.9% of sales, these milestones may support future product adoption and portfolio differentiation.
Bears Say
Severe Profitability Deterioration
The large TTM net loss and declining revenue indicate that recent earnings power has weakened substantially from prior profitable periods. Even with solid gross margin, sustained operating losses can constrain reinvestment, reduce resilience, and make balance-sheet improvement more dependent on execution.
Interventional Integration And Growth Pressure
The prolonged VI integration is affecting order-to-cash processes, distributor transitions and sales-force alignment, limiting near-term Interventional performance. Lower company-wide revenue guidance signals that execution challenges could persist across the next several quarters and delay expected growth benefits.
Higher Leverage And Weaker Coverage
Although divestiture proceeds support debt reduction, Teleflex still carries materially higher leverage than in earlier years and has weaker obligation coverage. This combination reduces financial flexibility, increases dependence on consistent cash generation, and leaves less room for operating setbacks or integration costs.
Teleflex News
TFX FAQ
What was Teleflex’s price range in the past 12 months?
What is Teleflex’s market cap?
When is Teleflex’s upcoming earnings report date?
How were Teleflex’s earnings last quarter?
Is Teleflex overvalued?
Does Teleflex pay dividends?
What is Teleflex’s EPS estimate?
How many shares outstanding does Teleflex have?
What happened to Teleflex’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Teleflex?
What is the TipRanks Smart Score and how is it calculated?
Teleflex Stock Smart Score
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Jason Weidman
- Employees
- 15,500
- Website
- www.teleflex.com
- Address
- 550 East Swedesford Road, Wayne, PA, 19087-1603, US
Teleflex (TFX) Earnings & Revenues
TFX Company Deck
TFX Earnings Call
Earnings Call SentimentPositive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.
View all MX:TFX earnings summariesTFX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 6 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 10 | 0 | 2 |
